Table 7.
Phase 2 tivozanib randomized discontinuation trial (Bhargava et al., 2010; Bhargava and Robinson, 2011).
| Patient group | Patient no. | Median PFS (months) | ORR (%) |
|---|---|---|---|
| All patients | 272 | 11.8 (95% CI; 253–450 days) | 27 |
| HISTOLOGIC SUBSETS | |||
| Clear cell | 226 | 12.5 | 29 |
| Non-clear cell | 46 | 6.7 | 17 |
| PRIOR THERAPY (CLEAR CELL) | |||
| Treatment naïve | 77 | 14.3 | 43 |
| ≥1 Prior therapy | 99 | 15.9 | 23 |
| PRIOR NEPHRECTOMY | |||
| Yes | 199 | 14.1 | 30 |
| No | 73 | 8.2 | 18 |
| Prior nephrectomy + clear cell carcinoma | 176 | 14.8 | 32 |
CI, confidence interval; ORR, overall response rate.